We regularly share the progress of our current research. Use the links on this page to learn about the latest research we've unveiled.
E. Evans, et al. Clinical Development of AVL-292: A Potent, Selective Covalent Btk Inhibitor for the treatment of B Cell Malignancies, ASH Annual Meeting, Dec 10-13, San Diego, California.
H. Eda, et al. Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma, ASH Annual Meeting, Dec 10-13, San Diego, California.
E. Evans, et al. Translation Medicine of a Selective Inhibitor of Btk in Rheumatic Diseases: Pharmacology and Early Clinical Development. American College of Rheumatology, November 5-9, Chicago, Illinois.
M. Labenski, et al. InVitro Reactivity Assessment of Covalent Drugs Targeting Bruton's Tyrosine Kinase. 17th North America Regional Meeting of International Society for the Study of Xenobiotics, October 16-20, Atlanta, Georgia.
E. Evans, et al. AVL-292: A Targeted Therapy For Bruton's Tyrosine Kinase in B Cell Malignancies. 16th Congress of the European Hematology Association, London UK.
E. Evans, et al. Bruton's Tyrosine Kinase from Bench to Bedside: Covalently Silencing B Cells with AVL-292. Keystone Symposium: B Cells: New Insights into Normal vs. Dysregulated Function, April 12-17th, Whistler, BC.